Kamal Ghorui
BofA maintained its buy recommendation on Infosys with the target price at Rs 1,840. Analysts said there were several positives on positioning and net opportunity could be bigger but the path is still evolving. They also said that enterprise AI isn’t plug and play. Currently revenue from AI-first offerings stands at 5.5%, which is not too different from others that have disclosed the metric. Analysts also warned that the key risk with AI, as per the company, is less about opportunity and more about strategy and execution. They also believe the Anthropic partnerships signify the role of a services company in enterprise AI shift.UBS has a buy on ITC with the target price cut to Rs 395 from Rs 420. Analysts said their distributor checks indicated a range of imminent price hikes, which is now arriving. ITC’s 84mm cigarettes are expected to be priced at Rs 24 per stick, up from Rs 17 earlier. This segment has seen the steepest tax increase. While on the other extreme, 64mm is expected to be priced Rs 7 per stick, from Rs 5.9 earlier. The pricing of 69mm Goldflake (a large volume driver, currently at Rs 9.5 per stick) is yet to be known. They expect it to be priced around Rs 12. It is clear that price hikes have been fully passed on in the premium cigarettes, while it is kept minimal in price sensitive segments of 69mm and 64mm. This pricing approach is likely to keep ITC’s volume and earnings before interest and taxes (EBIT) impact to minimum.Goldman Sachs has initiated its coverage of LG Electronics with the target price at Rs 1,750. Analysts said the company is well-placed to grow faster than the industry in the near to medium term. This could come due to shifting income cohort mix and rising penetration leading to faster industry growth in the mid and premium products. Also due to the company’s consistent track record of innovation enabling it to sustain its premiumization trends. A third reason could be LG Electronics Inc’s ‘Global South’ strategy, which should enable it to improve exports while expanding its manufacturing in India. However, analysts warned that the rising competitive intensity in an increasing commodity price environment should keep margin expansion potential limited.Morgan Stanley has an underweight rating on Dabur with the target price at Rs 400. Analysts said Mohit Malhotra (currently Whole Time Director & CEO) has been re-designated as Whole Time Director & Global CEO, effective Feb 17, 2026. Herjit S Bhalla has been appointed as CEO – India Business, effective April 15, 2026 or such other date as may be mutually agreed. They said that Bhalla brings more than 25 years of experience across sales, marketing and general management roles.HSBC has a buy on Aurobindo Pharma with the target price raised to Rs 1,415. Analysts said the company received US FDA approval for Adquey (difamilast 1%), a non-steroid topical treatment for atopic dermatitis. They feel Adquey has potential to become a $250-300-million brand but Aurobindo Pharma needs to invest for specialist sales hires. Analysts also feel marketing execution will be the key for Adquey’s success in the US.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)
